New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 27, 2014
15:12 EDTHSP, FMS, DANOY, NSRGY Hospira in talks to acquire Danone medical nutrition business, FT says
French consumer company Danone (DANOY) has been in negotiations to sell its medical nutrition business to Hospira (HSP) in a deal said to value the unit at $5B, says the Financial Times. The deal would also allow for U.S. based Hospira to domicile its tax base in Europe in a tax strategy known as an inversion, added the Financial Times. In prior reports, Nestle (NSRGY) and Fresenius (FMS) have also been mentioned as suitors for the Danone unit. Reference Link
News For DANOY;HSP;NSRGY;FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
16:15 EDTHSPHospira: No Form 483 observations issued after inspection of Costa Rica facility
Subscribe for More Information
09:58 EDTFMSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTFMSFresenius Medical upgraded to Neutral from Underweight at HSBC
Subscribe for More Information
February 26, 2015
09:41 EDTHSPHospira launches generic Remicade, WSJ says
Subscribe for More Information
February 22, 2015
17:31 EDTNSRGYNestle looks to boost productivity in Switzerland, Reuters says
Subscribe for More Information
February 20, 2015
06:25 EDTDANOYDanone board to ask shareholders to approve increased dividend of EUR1.50
Subscribe for More Information
06:24 EDTDANOYDanone targets 2015 organic growth in sales of between 4%-5%
Danone assumes that economic conditions will remain difficult and unstable overall, with fragile or even deflationary consumer trends in Europe, emerging markets undermined by volatile currencies, and difficulties specific to a few major markets, in particular the CIS. In 2015, Danone also anticipates marked but varied trends in the cost of major strategic raw materials, particularly milk; lower prices in Europe and the United States in the first half, with a rebound likely in the second half of the year, and gradual price increases in emerging countries all year long. Altogether, Danone anticipates a moderate rise in the cost of main raw materials and packaging in 2015. Sees slight growth in trading operating margin in 2015.
06:22 EDTDANOYDanone reports FY14 EPS EUR2.62
Subscribe for More Information
06:18 EDTDANOYDanone warns of volatility in years ahead, sees 'difficult' conditions in 2015
Subscribe for More Information
February 19, 2015
07:06 EDTFMSFresenius Medical reports data on DHR pilot, plans expansion
Subscribe for More Information
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
05:36 EDTNSRGYNestle aims to achieve organic growth of around 5%
Subscribe for More Information
05:35 EDTNSRGYNestle reports FY14 organic growth of 4.5%
Nestlé'sFY14 organic growth was 4.5%, composed of 2.3% real internal growth and 2.2% pricing. Sales were CHF 91.6B, down 0.6%, impacted by negative foreign exchange of -5.5%. Acquisitions, net of divestitures, added 0.4% to sales.
February 18, 2015
10:05 EDTDANOYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
08:41 EDTHSPThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
06:01 EDTDANOYDanone upgraded to Neutral from Underperform at Exane BNP Paribas
Subscribe for More Information
February 17, 2015
04:47 EDTHSPPfenex price target raised to $16 from $12 at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use